Using antimicrobial host defense peptides as anti-infective and immunomodulatory agents

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 6, 2008, Pages 887-895

  Kruse, Thomas ^a   Kristensen, Hans Henrik ^a  

^a NOVOZYMES A S   (Denmark)

Author keywords

Antibiotic resistance; Antibiotics; Host defense peptide; Immunomodulation; Pattern recognition receptor

Indexed keywords

CHEMOKINE RECEPTOR CCR6; DEFENSIN; HUMAN NEUTROPHIL PEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTOFERRIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; OFLOXACIN; OMIGANAN; OVALBUMIN; PEXIGANAN; POLYPEPTIDE ANTIBIOTIC AGENT; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; IMMUNOLOGIC FACTOR; PATTERN RECOGNITION RECEPTOR;

ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ANTIMICROBIAL ACTIVITY; ATOPIC DERMATITIS; CATHETER INFECTION; CELL MATURATION; CHEMOTAXIS; CLINICAL TRIAL; CROHN DISEASE; DENDRITIC CELL; DIABETIC FOOT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SAFETY; EPITHELIUM CELL; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; KERATINOCYTE; MACROPHAGE; MAST CELL; MEMORY T LYMPHOCYTE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PANETH CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; IMMUNOTHERAPY; INFECTION; PHYSIOLOGY;

ANTIMICROBIAL CATIONIC PEPTIDES; CLINICAL TRIALS AS TOPIC; DEFENSINS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INFECTION; RECEPTORS, PATTERN RECOGNITION;

EID: 85047685350     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.6.887     Document Type: Review

References (84)

1. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 442(7098), 39-44 (2006).
2. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 449(7164), 819-826 (2007).
3. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415(6870), 389-395 (2002).
4. Matsuzaki K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim. Biophys. Acta 1462(1-2), 1-10 (1999).
5. Yang L, Weiss TM, Lehrer RI, Huang HW. Crystallization of antimicrobial pores in membranes: magainin and protegrin. Biophys. J. 79(4), 2002-2009 (2000).
6. Kragol G, Lovas S, Varadi G. Condie BA. Hoffmann R, Otvos L Jr. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry 40(10), 3016-3026 (2001).
7. del Castillo FJ, del Castillo I, Moreno F. Construction and characterization of mutations at codon 751 of the Escherichia coli gyrB gene that confer resistance to the antimicrobial peptide microcin B17 and alter the activity of DNA gyrase. J. Bacteriol. 183(6), 2137-2140 (2001).
8. Peschel A, Sahl HG. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat. Rev. Microbiol. 4(7), 529-536 (2006).
9. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis, N. Engl. J. Med. 347(15), 1151-1160 (2002).
10. Wehkamp J, Salzman NH, Porter E et al. Reduced Paneth cell α-defensins in ileal Crohn's disease. Proc. Natl Acad. Sci. USA 102(50), 18129-18134 (2005).
11. Reichert JM. Trends in development and approval times for new therapeutics in the United States. Nat. Rev. Drug Discov. 2(9), 695-702 (2003).
12. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7(1), 21-39 (2008).
13. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 1(6), 457-462 (2002).
14. Zhang L, Falla TJ. Antimicrobial peptides: therapeutic potential. Expert Opin. Pharmacother. 7(6), 653-663 (2006).
15. Mygind PH, Fischer RL, Schnorr KM et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437(7061), 975-980 (2005).
16. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24(12), 1551-1557 (2006).
17. Ge Y, MacDonald DL, Holroyd KJ, Thornsberry C, Wexler H, Zasloff M. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother. 43(4), 782-788 (1999).
18. Ganz T, Selsted ME, Szklarek D et al. Defensins. Natural peptide antibiotics of human neutrophils. J. Clin. Invest. 76(4), 1427-1435 (1985).
19. Wilde CG, Griffith JE, Marra MN, Snable JL, Scott RW. Purification and characterization of human neutrophil peptide 4, a novel member of the defensin family. J. Biol. Chem. 264(19), 11200-11203 (1989).
20. Jones DE, Bevins CL. Paneth cells of the human small intestine express an antimicrobial peptide gene. J. Biol. Chem. 267(32), 23216-23225 (1992).
21. Jones DE, Bevins CL. Defensin-6 mRNA in human Paneth cells: implications for antimicrobial peptides in host defense of the human bowel. FEBS Lett. 315(2), 187-192 (1993).
22. Bensch KW, Raida M, Magert HJ, Schulz-Knappe P, Forssmann WG. hBD-1: a novel β-defensin from human plasma. FEBS Lett. 368(2), 331-335 (1995).
23. Zhao C, Wang I, Lehrer RI. Widespread expression of β-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett. 396(2-3), 319-322 (1996).
24. Harder J, Barrels J, Christophers E, Schroder JM. A peptide antibiotic from human skin. Nature 387(6636), 861 (1997).
25. Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr. Opin. Immunol. 14(1), 96-102 (2002).
26. Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J. Human β-defensins. Cell Mol. Life Sci. 63(11), 1294-1313 (2006).
27. Lehrer RI. Primate defensins. Nat. Rev. Microbiol. 2(9), 727-738 (2004).
28. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783-801 (2006).
29. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388(6640), 394-397 (1997).
30. Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4(7), 499-511 (2004).
31. Moynagh PN. The NF-κB pathway. J. Cell Sci. 118(Pt 20), 4589-4592 (2005).
32. Singh PK, Jia HP, Wiles K et al. Production of β-defensins by human airway epithelia. Proc. Natl Acad. Sci. USA 95(25), 14961-14966 (1998).
33. Dunsche A, Acil Y, Siebert R, Harder J, Schroder JM, Jepsen S. Expression profile of human defensins and antimicrobial proteins in oral tissues. J. Oral Pathol. Med. 30(3), 154-158 (2001).
34. Chalifour A, Jeannin P, Gauchat JF et al. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers α-defensin production. Blood 104(6), 1778-1783 (2004).
35. Rodriguez-Garcia M, Oliva H, Climent N, Garcia F, Gatell JM, Gallart T. Human immature monocyte-derived dendritic cells produce and secrete α-defensins 1-3. J. Leukoc. Biol. 82(5), 1143-1146 (2007).
36. Froy O. Regulation of mammalian defensin expression by Toll-like receptor-dependent and independent signalling pathways. Cell Microbiol. 7(10), 1387-1397 (2005).
37. Cook AD, Braine EL, Hamilton JA. Stimulus-dependent requirement for granulocyte - macrophage colony-stimulating factor in inflammation. J. Immunol. 173(7), 4643-4651 (2004).
38. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 17(4), 338-344 (2005).
39. Jang BC, Lim KJ, Paik JH et al. Up-regulation of human β-defensin 2 by interleukin-1β in A549 cells: involvement of PI3K, PKC, p38 MAPK, JNK, and NF-κB. Biochem. Biophys. Res. Commun. 320(3), 1026-1033 (2004).
40. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat. Immunol. 7(12), 1250-1257 (2006).
41. Wehkamp J, Harder J, Weichenthal M et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal α-defensin expression. Gut 53(11), 1658-1664 (2004).
42. Kobayashi KS, Chamaillard M, Ogura Y et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307(5710), 731-734 (2005).
43. Bowdish DM, Davidson DJ; Hancock RE. Immunomodulatory properties of defensins and cathelicidins. Curr. Top. Microbiol. Immunol. 306, 27-66 (2006).
44. Mookherjee N, Hancock RE. Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell Mol. Life Sci. 64(7-8), 922-933 (2007).
45. Niyonsaba F, Ushio H, Nakano N et al. Antimicrobial peptides human β-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J. Invest. Dermatol. 127(3), 594-604 (2007).
46. Niyonsaba F, Ushio H, Nagaoka I, Okumura K, Ogawa H. The human β-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J. Immunol. 175(3), 1776-1784 (2005).
47. Van WS, Mannesse-Lazeroms SP, Dijkman JH, Hiemstra PS. Effect of neutrophil serine proteinases and defensins on lung epithelial cells: modulation of cytotoxicity and IL-8 production. J. Leukoc. Biol. 62(2), 217-226 (1997).
48. Sakamoto N, Mukae H, Fujii T et al. Differential effects of α- and β-defensin on cytokine production by cultured human bronchial epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 288(3), L508-L513 (2005).
49. Liu CY, Lin HC, Yu CT et al. The concentration-dependent chemokine release and pro-apoptotic effects of neutrophil-derivedα-defensin-1 on human bronchial and alveolar epithelial cells. Life Sci. 80(8), 749-758 (2007).
50. Shi J, Aono S, Lu W et al. A novel role for defensins in intestinal homeostasis: regulation of IL-1β secretion. J. Immunol. 179(2), 1245-1253 (2007).
51. Chertov O, Michiel DF, Xu L et al. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J. Biol. Chem. 271(6), 2935-2940 (1996).
52. Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J. Leukoc. Biol. 68(1), 9-14 (2000).
53. Grigat J, Soruri A, Forssmann U, Riggert J, Zwirner J. Chemoattraction of macrophages, T lymphocytes, and mast cells is evolutionarily conserved within the human α-defensin family. J. Immunol. 179(6), 3958-3965 (2007).
54. Yang D, Chertov O, Bykovskaia SN et al. β-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286(5439), 525-528 (1999).
55. Soruri A, Grigat J, Forssmann U, Riggert J, Zwirner J. β-defensins chemoattract macrophages and mast cells but not lymphocytes and dendritic cells: CCR6 is not involved. Eur. J. Immunol. 37(9), 2474-2486 (2007).
56. Flower RJ, Harvey EA, Kingston WP. Inflammatory effects of prostaglandin D2 in rat and human skin. Br. J. Pharmacol. 56(2), 229-233 (1976).
57. Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I. Evaluation of the effects of peptide antibiotics human β-defensins-1/-2 and LL-37 on histamine release and prostaglandin D2 production from mast cells. Eur. J. Immunol. 31(4), 1066-1075 (2001).
58. Chen X, Niyonsaba F, Ushio H et al. Antimicrobial peptides human β-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular permeability. Eur. J. Immunol. 37(2), 434-444 (2007).
59. Spencer LT, Paone G, Krein PM, Rouhani FN, Rivera-Nieves J, Brantly ML. Role of human neutrophil peptides in lung inflammation associated with α1-antitrypsin deficiency. Am. J. Physiol. Lung Cell Mol. Physiol. 286(3), L514-L520 (2004).
60. Flamand L, Borgeat P, Lalonde R, Gosrelin J. Release of anti-HIV mediators after administration of leukotriene B4 to humans. J. Infect. Dis. 189(11), 2001-2009 (2004).
61. Flamand L, Tremblay MJ, Borgeat P. Leukotriene B4 triggers the in vitro and in vivo release of potent antimicrobial agents. J. Immunol. 178(12), 8036-8045 (2007).
62. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protecrin D1 activate inflammation-resolution programmes. Nature 447(7146), 869-874 (2007).
63. Rajakariar R, Hilliard M, Lawrence T et al. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyδ12 14 PGJ2. Proc. Natl Acad. Sci. USA 104(52), 20979-20984 (2007).
64. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311, 17-58 (2006).
65. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440(7085), 808-812 (2006).
66. Chaly YV, Paleolog EM, Kolesnikova TS, Tikhonov II, Petratchenko EV, Voitenok NN. Neutrophil α-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur. Cytokine Netw. 11(2), 257-266 (2000).
67. Funderburg N, Lederman MM, Feng Z et al. Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc. Natl Acad. Sci. USA 104(47), 18631-18635 (2007).
68. Biragyn A, Coscia M, Nagashima K, Sanford M, Young HA, Olkhanud P. Murine β-defensin 2 promotes TLR-4/MyD88-mediated and NF-κB-dependent atypical death of APCs via activation of TNFR2. J. Leukoc. Biol. 83(4), 998-1008 (2008).
69. Lillard JW Jr, Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc. Natl Acad. Sci. USA 96(2), 651-656 (1999).
70. Brogden KA, Heidari M, Sacco RE et al. Defensin-induced adaptive immunity in mice and its potential in preventing periodontal disease. Oral Microbiol. Immunol. 18(2), 95-99 (2003).
71. Candille SI, Kaelin CB, Cattanach BM et al. A β-defensin mutation causes black coat color in domestic dogs. Science 318(5855), 1418-1423 (2007).
72. van den Berg RH, Faber-Krol MC, Van Wetering S, Hiemstra PS, Daha MR. Inhibition of activation of the classical pathway of complement by human neutrophil defensins. Blood 92(10), 3898-3903 (1998).
73. Groeneveld TW, Ramwadhdoebe TH, Trouw LA et al. Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation. Mol. Immunol. 44(14), 3608-3614 (2007).
74. Tecle T, White MR, Gantz D, Crouch EC, Hartshorn KL. Human neutrophil defensins increase neutrophil uptake of influenza A virus and bacteria and modify virus-induced respiratory burst responses. J. Immunol. 178(12), 8046-8052 (2007).
75. Finlay BB, Hancock RE. Can innate immunity be enhanced to treat microbial infections? Nat. Rev. Microbiol. 2(6), 497-504 (2004).
76. Oda K, Kitano H. A comprehensive map of the Toll-like receptor signaling network. Mol. Syst. Biol. 2, 2006 (2006).
77. Brown KL, Cosseau C, Gardy JL, Hancock RE. Complexities of targeting innate immunity to treat infection. Trends Immunol. 28(6), 260-266 (2007).
78. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172(5), 2731-2738 (2004).
79. Scott MG, Dullaghan E, Mookherjee N et al. An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol. 25(4), 465-472 (2007).
80. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13(5), 552-559 (2007).
81. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5(6), 471-484 (2006).
82. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124(4), 849-863 (2006).
83. Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int. J. Antimicrob. Agents 29(6), 630-636 (2007).
84. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6(1), 29-40 (2007).